Calcitriol-Mediated Hypercalcemia, Somatostatin Receptors Expression and 25-Hydroxyvitamin D
GIST tumor
calcitriol
corticoids
hypercalcemia
somatostatin receptors
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
11
2021
accepted:
23
12
2021
entrez:
14
2
2022
pubmed:
15
2
2022
medline:
1
4
2022
Statut:
epublish
Résumé
Hypercalcemia is a common complication in cancer patients Mainly caused by Parathyroid hormone-related protein (PTHrP) secretion and metastasis. Calcitriol secretion is a rare source of hypercalcemia in solid tumors, especially in gastrointestinal stromal tumors (GIST). We present a case report of a female patient with a 23 cm gastric GIST that expressed somatostatin-receptors and presented with severe hypercalcemia due to calcitriol secretion. Calcium control was achieved with medical treatment before the use of targeted-directed therapies. Surgery was performed and allowed complete tumor resection. Two years later, patient remains free of disease. Molecular analysis revealed the mRNA expression of 25-hydroxyvitamin D
Identifiants
pubmed: 35154010
doi: 10.3389/fendo.2021.812385
pmc: PMC8826724
doi:
Substances chimiques
Receptors, Somatostatin
0
Vitamin D
1406-16-2
25-hydroxyvitamin D
A288AR3C9H
Mixed Function Oxygenases
EC 1.-
Calcitriol
FXC9231JVH
Calcifediol
P6YZ13C99Q
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
812385Informations de copyright
Copyright © 2022 Herrera-Martínez, Contreras González, Pedraza-Arévalo, Guerrero Martínez, Rodrigo Martínez, González Menchen, Blanco Molina, Gálvez-Moreno, Moreno-Vega, Luque and Herrera-Martínez.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2005 Jan 27;352(4):373-9
pubmed: 15673803
Emerg Med Clin North Am. 2014 Aug;32(3):509-25
pubmed: 25060247
Blood. 1993 Sep 1;82(5):1383-94
pubmed: 8364192
Saudi Med J. 2006 Oct;27(10):1585-7
pubmed: 17013488
Clin Endocrinol (Oxf). 2007 Jan;66(1):148
pubmed: 17201815
Endocr Pract. 2013 Nov-Dec;19(6):e158-62
pubmed: 24013983
BMC Cancer. 2015 Oct 24;15:788
pubmed: 26499069
J Clin Endocrinol Metab. 2021 Oct 21;106(11):3113-3128
pubmed: 34240162
Case Rep Oncol Med. 2017;2017:4972017
pubmed: 28484656
J Exp Med. 1985 Apr 1;161(4):755-65
pubmed: 3838552
Surgery. 2006 Apr;139(4):484-92
pubmed: 16627057
Science. 1998 Jan 23;279(5350):577-80
pubmed: 9438854
J Clin Endocrinol Metab. 2015 May;100(5):2024-9
pubmed: 25719931
Cancer Epidemiol. 2016 Feb;40:39-46
pubmed: 26618334
J Clin Invest. 1990 May;85(5):1588-93
pubmed: 2159024
Proc Natl Acad Sci U S A. 1971 Apr;68(4):803-4
pubmed: 4323790
Am J Transl Res. 2014 Nov 22;6(6):831-40
pubmed: 25628793
N Engl J Med. 2001 Apr 5;344(14):1052-6
pubmed: 11287975
Am J Pathol. 2004 Sep;165(3):807-13
pubmed: 15331405
Calcif Tissue Int. 1985 Dec;37(6):588-91
pubmed: 3937578
Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1885-9
pubmed: 11734441
Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):e123-e129
pubmed: 29361495
Clin Oncol (R Coll Radiol). 2008 May;20(4):317-8
pubmed: 18339524
J Clin Endocrinol Metab. 2013 Oct;98(10):4023-9
pubmed: 23979953